Target Name: WFDC3
NCBI ID: G140686
Review Report on WFDC3 Target / Biomarker Content of Review Report on WFDC3 Target / Biomarker
WFDC3
Other Name(s): WAP four-disulfide core domain protein 3 | putative protease inhibitor WAP14 | Whey acidic protein 14 | DJ447F3.3 | Protease inhibitor WAP14 | dJ447F3.3 | WFDC3_HUMAN | protease inhibitor WAP14 | WAP four-disulfide core domain 3 | whey acidic protein 14 | Putative protease inhibitor WAP14 | WAP14

WFDC3: A Protein Targeted for Cancer and Neurodegenerative Diseases

WFDC3, which stands for WAP four-disulfide core domain protein 3, is a protein that is expressed in various tissues and cells in the human body. It is a member of the WAP (WASP-associated protein) family, which is known for their role in various cellular processes, including cell signaling, cell adhesion, and cytoskeletal organization. While much is still known about WFDC3 and its functions, it has been shown to play a crucial role in the development and progression of various diseases, including cancer. As As a result, WFDC3 has emerged as a promising drug target and biomarker.

Structure and Localization

WFDC3 is a four-dimensional protein that consists of a N-terminal domain, a C-terminal domain, a D1 domain, and a D2 domain. The N-terminal domain is made up of 21 amino acids and is located at the protein's amino terminal. The C-terminal domain is made up of 22 amino acids and is located at the protein's carboxy terminal. The D1 domain is made up of 19 amino acids and is located in the middle of the protein. The D2 domain is made up of 22 amino acids and is located in the middle of the protein.

WFDC3 is expressed in various tissues and cells throughout the body, including the liver, pancreas, and intestine. It is also expressed in various types of cancer, including colon cancer, breast cancer, and skin cancer. Additionally, it has been shown to be involved in various cellular processes, including cell signaling, cell adhesion, and cytoskeletal organization.

Function

WFDC3 has been shown to play a crucial role in the development and progression of various diseases, including cancer. It has been shown to promote the growth and survival of cancer cells, and it has been shown to contribute to the development of cancer stem cells. WFDC3 has also been shown to play a role in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Drug Targeting

WFDC3 is a drug target that has the potential to be used for the treatment of various diseases, including cancer. Because it is involved in the development and progression of these diseases, it has been shown to be a good candidate for drug targeting. various methods , including cell-based assays, in vitro assays, and animal models, have been used to study the effects of drugs on WFDC3. These methods have shown that WFDC3 can be effectively targeted with various drugs, including small molecules, peptides, and antibodies.

Biomarker

WFDC3 has also been shown to be a potential biomarker for various diseases, including cancer. Its expression has been shown to be associated with the development and progression of these diseases, and it has been shown to be a reliable indicator of disease severity in various types of cancer. Additionally, it has been shown to be a potential biomarker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

WFDC3 is a protein that is involved in various cellular processes throughout the body. Its functions have been shown to be crucial in the development and progression of various diseases, including cancer. As a result, WFDC3 has emerged as a promising drug target and biomarker. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: WAP Four-disulfide Core Domain 3

The "WFDC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WFDC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697